Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Market Cap	$161.52M	P/E Ratio	N/A
52W High	$2.84	52W Low	$0.38
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	26.4%	52W Position	2.7%
Overall Score	32	Value Score	40
Quality Score	39	Technical Score	18

EPS Current Est	$-0.37	EPS Next Est	$-0.25
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGMO	$0.45	-1.98%	4.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SGMO	$0.45	-2.0%	4.44M
3
4
5
6

SGMO

SGMO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sangamo Therapeutics Inc. Data in Excel

Get Sangamo Therapeutics Inc. Data in Excel